SCHEMBL4055498

SCHEMBL4055498

Cn1ccc2c3nc(-c4cnc(O)nc4)nc(N4CCOCC4)c3ccc21

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 19/20 0.50
MTOR P42345 4/20 0.49
PIK3CD O00329 4/20 0.43
PIK3CG P48736 4/20 0.43
PIK3CB P42338 2/20 0.43
PIK3C2B O00750 1/20 0.41
HDAC3 O15379 1/20 0.41
PIK3R1 P27986 1/20 0.41
PRKDC P78527 1/20 0.41
HDAC1 Q13547 1/20 0.41
PIK3C3 Q8NEB9 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
NCOR2 Q9Y618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4048892 0.90 MTOR (0.49) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL4056512 0.90 PIK3CA (0.64) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL4049973 0.88 PIK3CA (0.48) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL4059885 0.86 PIK3CA (0.54) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL4059089 0.85 PIK3CA (0.50) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL4057772 0.84 HDAC1 (0.48) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL4049643 0.84 PIK3CA (0.58) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL4050610 0.83 MTOR (0.57) PIK3CAMTORPIK3CGPIK3R1
SCHEMBL4053455 0.83 MTOR (0.52) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL4053156 0.82 PIK3CA (0.46) PIK3CAMTORPIK3CDPIK3CGPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009111547-A1 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS WYETH (US) 2009-09-11 WO claimed
US-20090227575-A1 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS WYETH (US) 2009-09-10 US claimed
WO-2009111547-A1 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS WYETH (US) 2009-09-11 WO disclosed
US-20090227575-A1 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS WYETH (US) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227575-A1 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS MTOR, RICTOR, RPS6KA3 PIK3CA 19/4885MTOR 1/4885PIK3CD 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.